- Home
- ADXN vs INTS Comparison
ADXN vs INTS Comparison
Compare ADXN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- INTS
- Stock Information
- Founded
- ADXN 2002
- INTS 2012
- Country
- ADXN Switzerland
- INTS United States
- Employees
- ADXN N/A
- INTS N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- INTS Health Care
- Exchange
- ADXN Nasdaq
- INTS Nasdaq
- Market Cap
- ADXN 8.1M
- INTS 9.4M
- IPO Year
- ADXN N/A
- INTS 2023
- Fundamental
- Price
- ADXN $9.00
- INTS $0.32
- Analyst Decision
- ADXN Strong Buy
- INTS Strong Buy
- Analyst Count
- ADXN 1
- INTS 3
- Target Price
- ADXN $30.00
- INTS $8.50
- AVG Volume (30 Days)
- ADXN 7.6K
- INTS 2.7M
- Earning Date
- ADXN 06-19-2025
- INTS 08-07-2025
- Dividend Yield
- ADXN N/A
- INTS N/A
- EPS Growth
- ADXN N/A
- INTS N/A
- EPS
- ADXN 0.10
- INTS N/A
- Revenue
- ADXN $278,508.00
- INTS N/A
- Revenue This Year
- ADXN $86.57
- INTS N/A
- Revenue Next Year
- ADXN N/A
- INTS N/A
- P/E Ratio
- ADXN $0.74
- INTS N/A
- Revenue Growth
- ADXN N/A
- INTS N/A
- 52 Week Low
- ADXN $6.51
- INTS $0.26
- 52 Week High
- ADXN $13.27
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- ADXN 55.39
- INTS 37.08
- Support Level
- ADXN $8.02
- INTS $0.28
- Resistance Level
- ADXN $9.78
- INTS $0.32
- Average True Range (ATR)
- ADXN 0.73
- INTS 0.06
- MACD
- ADXN 0.02
- INTS 0.01
- Stochastic Oscillator
- ADXN 32.94
- INTS 7.43
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.